HRH2 and COVID-19: Several observational studies of COVID-19 patients indicate famotidine, a selective histamine H2 receptor antagonist widely used to treat gastroesophageal reflux disease, improves survival in hospitalized patients and ameliorates symptoms in non-hospitalized patients (7, 8) when administered at a high dose.